(MYO) Myomo, Inc. Company Overview

What does Myomo do?

Myomo, Inc. is a wearable medical robotics company listed on the NYSE American as MYO. Its MyoPro family comprises custom-powered arm and hand orthoses for people with partial upper-limb paralysis from stroke, brachial plexus injury, spinal cord injury, cerebral palsy, and related conditions. Surface sensors detect the wearer’s muscle signals and motors assist intended elbow, wrist, or hand movement. MyoPro is therefore a non-invasive assistive brace, not a prosthesis or implant, as described in the company’s official product explanation.

Which products and patients define the business?

The flagship MyoPro 2x launched in April 2025. Motion W assists the elbow and supports wrist positioning; Motion G adds powered grasp. Every brace is measured, fabricated, fitted, and supported for one patient, so Myomo combines hardware, clinical evaluation, reimbursement administration, custom manufacturing, training, and follow-up. Its company overview traces the underlying technology to MIT and Harvard Medical School.

Why does Myomo matter within medical devices?

Myomo serves patients who retain their limb and a measurable muscle signal but cannot generate enough force for daily activities. The 2025 filing identifies MyoPro as a Class II, 510(k)-exempt biofeedback device and says management believes it is the only commercially available U.S. product using a patient’s own signals to restore weak arm and hand movement. At year-end 2025, Myomo reported 35 issued patents expiring from 2027 through 2042 and 14 pending applications. The combination of intellectual property, clinical workflow, payer coding, and custom fabrication matters more than scale; details appear in the 2025 Form 10-K.

How does Myomo make money?

Myomo recognizes revenue when a completed MyoPro is delivered and accounting criteria are met. Under direct billing, it evaluates the patient, coordinates documentation, fabricates and delivers the brace, and bills the insurer. In the O&P channel, Myomo sells wholesale to an orthotics-and-prosthetics practice that provides local care and bills the payer. International distributors, Veterans Affairs facilities, and rehabilitation accounts are smaller channels.

What does the patient-to-cash process look like?

Demand must pass through clinical qualification, documentation, payer approval, fabrication, fitting, and collection. Backlog represents authorized or documented patients whose revenue has not yet been recognized.

Which revenue source is largest?

In FY2025, direct billing rose 20%, International revenue increased 48%, U.S. O&P approximately doubled, and VA revenue declined 31%. The strategy is to preserve direct billing while replacing part of paid advertising with repeat referrals, O&P partners, and international providers.

What does Myomo’s latest quarter show?

For the quarter ended March 31, 2026, revenue rose 3% to $10.1 million, gross profit increased 4% to $6.9 million, and gross margin reached 68.2% versus 67.2%. Revenue units fell 5% to 172, while average selling price increased 9% to about $58,800. Pricing and channel mix, rather than volume, drove growth.

What changed operationally in Q1 2026?

Recurring sources generated 49% of Q1 2026 revenue versus 25% a year earlier. Direct-billing referrals produced 11% of pipeline additions and 16% of orders, early evidence that MyoConnect and partner referrals may improve lead quality. Myomo also disclosed roughly 158 million covered lives expected under in-network access after pending contracts close. The Q1 2026 earnings release contains the operating scorecard.

How should the margin signal be read?

Gross margin must support a large fixed cost base. Q1 2026 operating expenses were $10.1 million: $1.6 million of R&D, $4.8 million of selling, clinical, and marketing expense, and $3.6 million of G&A. The model needs revenue growth without proportional expense growth. Management reaffirmed FY2026 revenue guidance of $43 million to $46 million and guided Q2 revenue to $10.3 million to $10.8 million. Balance-sheet and risk details appear in the Q1 2026 Form 10-Q.

Reimbursement economics define Myomo’s business model

Myomo’s opportunity is clinically driven but payer dependent because the brace’s price makes insurance coverage central to adoption. Medicare Part B represented 54% of FY2025 revenue and 51% of Q1 2026 revenue; Medicare Advantage added about 18% of Q1 revenue. That concentration is both the largest growth channel and a material policy risk.

Why was Medicare reclassification a strategic turning point?

MyoPro’s HCPCS codes were initially treated as durable medical equipment, implying capped-rental reimbursement. CMS moved them to the brace benefit effective January 1, 2024, enabling lump-sum payment. National rates effective April 1, 2024 were $33,480.90 for L8701 and $65,871.74 for L8702, as detailed in Myomo’s reimbursement announcement. Medicare generally pays 80%, with supplemental coverage, Medicaid, or the patient potentially responsible for the remainder.

Where is payer risk concentrated?

CMS represented about 36% of receivables at March 31, 2026, creating collection and audit exposure after revenue recognition. Commercial insurers may require preauthorization, network status, and case-specific medical-necessity review; German statutory insurers and trial periods add another timing layer. Payer access, denial rates, authorization speed, and days sales outstanding therefore belong in operating forecasts.

Which turning points shaped Myomo’s strategy?

Myomo’s current model is the product of repeated shifts in product design, distribution, reimbursement, and capital structure. The relevant history is not the chronology itself; it is how each milestone altered the route from clinical technology to reimbursed revenue.

1. 2004
   Myomo was incorporated to commercialize myoelectric technology developed at MIT in collaboration with Harvard Medical School specialists.
2. 2006
   The company completed licensing of core technology from MIT, establishing the intellectual-property foundation for later product development.
3. 2012
   MyoPro launched and the business shifted from rehabilitation devices sold to hospitals toward an assistive orthosis used in daily life.
4. 2015
   Motion W and Motion G expanded the product from elbow assistance to wrist support and powered grasp, increasing functional breadth and reimbursement value.
5. 2017
   The company completed its IPO, introduced MyoPro 2, and established European conformity, creating public-market funding and international access.
6. 2018–19
   CMS issued HCPCS codes L8701 and L8702, giving the product dedicated billing identifiers but initially classifying it under rental-oriented DME rules.
7. 2024
   Brace-category classification and lump-sum Medicare fees opened a much larger direct-billing opportunity and made Medicare Part B the dominant payer source.
8. 2025
   MyoPro 2x, MyoConnect, expanded Burlington manufacturing capacity, and Avenue debt financing marked a new phase focused on scale, recurring referrals, and operating leverage.

The strategic tension is clear: reimbursement validation enabled rapid revenue growth, but management expanded headcount, advertising, R&D, facilities, and working capital ahead of sustained profitability. FY2025 revenue grew 26%, yet operating loss widened to $14.4 million from $6.2 million. The next stage is therefore less about proving that MyoPro can be reimbursed and more about proving that the commercial system can produce positive cash flow.

What gives Myomo a competitive advantage?

Myomo’s advantage is a system rather than one patent: myoelectric control, custom orthotic engineering, clinical and reimbursement experience, dedicated HCPCS codes, direct billing, trained clinicians, O&P relationships, and supporting evidence. Each can be challenged, but reproducing the complete pathway is harder than copying a mechanical brace.

How durable is the moat?

At year-end 2025, 35 issued patents and 14 pending applications supported differentiation, while trade secrets covered control software and mechanical design. Clinical evidence and prescriber familiarity reinforce trust in a product that requires evaluation, fitting, and training; Myomo maintains an official research library. However, patents begin expiring in 2027, a European patent is under challenge, and Medicare pricing may attract larger entrants. The moat is meaningful, not impregnable.

Who are the main competitors and substitutes?

Myomo discloses no verified market share and remains a specialized pioneer rather than a scaled incumbent. Payers retain strong buyer power; custom fabrication creates labor and supplier constraints; clearer reimbursement may increase rivalry; and substitutes include therapy, passive braces, functional electrical stimulation, and emerging neurotechnology.

Which KPIs best explain Myomo’s performance?

Revenue alone can obscure the underlying funnel. Myomo must acquire or receive a referral, qualify the patient, obtain documentation or authorization, convert the order to backlog, fabricate and fit the device, recognize revenue, and collect cash. A weakness at any stage can appear months later in the income statement.

How do the funnel metrics connect?

What should researchers monitor next?

Read the sequence as a system: pipeline additions, referral share, acquisition cost, orders, backlog, revenue units, ASP, gross margin, and operating cash use. Lower lead cost without stable orders may indicate weaker quality; rising backlog without revenue can signal fitting constraints. Several metrics should improve together before the economics are considered durable.

How financially strong is Myomo?

Myomo has near-term liquidity but is not financially self-sustaining. At March 31, 2026, it held $11.4 million of cash and $4.3 million of short-term investments, for $15.7 million combined. Working capital was $16.3 million, equity was $9.0 million, and Q1 operating cash use improved to $2.2 million from $2.7 million.

Why did FY2025 growth not produce profitability?

FY2025 gross margin fell to 65.7% from 71.2% while operating expenses rose 40%. Advertising reached $8.0 million versus $3.5 million in FY2024, alongside investment in products, facilities, software, and personnel. The result shows that revenue growth is insufficient when acquisition cost, overhead, and R&D outpace gross profit.

What does the debt structure add to the analysis?

The Avenue facility commits up to $17.5 million. A $12.5 million tranche funded in November 2025; another $5.0 million is available from November 2026 to May 2027 if conditions are met. The loan matures June 1, 2029 and requires at least $2.5 million of unrestricted cash, 75% achievement of projected trailing three-month revenue, and cash-burn limits. Covenants link operating execution directly to financing flexibility, while principal conversion rights create dilution risk.

Capital allocation prioritizes growth and liquidity. Myomo has never paid a cash dividend, its debt restricts distributions, and management retains capital for product development and expansion. The key question is whether cash burn falls before covenant or liquidity pressure forces another financing.

Who owns Myomo stock, and why does governance matter?

Myomo has one class of common stock with one vote per share, so economic ownership and voting influence are broadly aligned. The investor base is not controlled by a founder or dual-class structure, but ownership is concentrated enough that several institutions and insiders can materially influence governance. The 2026 proxy used 38.6 million shares outstanding for its beneficial-ownership calculations.

The figures above are from Myomo’s 2026 proxy statement, based on ownership as of April 20, 2026. The proxy also states that the board had seven members, six of whom were considered independent. Paul Gudonis combines the chairman and CEO roles, while Thomas Kirk serves as lead independent director.

What governance signals should investors notice?

Governance matters because Myomo is financing-intensive and still loss-making. Decisions about spending, debt covenants, equity issuance, product investment, and commercial pace can materially change per-share value. Insider alignment is useful, but investors should also track dilution and whether compensation rewards sustainable cash-flow improvement rather than revenue growth alone.

What opportunities and risks could change Myomo’s outlook?

The upside case depends on converting reimbursement validation into a repeatable and less advertising-intensive growth engine. The downside case is that payer concentration, slow conversion, high fixed costs, and financing needs prevent the company from reaching sustainable cash generation before competitors or regulators change the economics.

Where could growth come from?

Which risks are most material?

The most important strategic trade-off is pace. Spending aggressively may accelerate referrals, evidence, product development, and channel adoption, but it raises financing risk. Cutting too quickly may preserve cash but weaken the commercial network required to create scale. Management’s stated 2026 goal—revenue growth with operating-expense growth at roughly half the rate and materially lower cash burn—captures the balancing act.

Why does Myomo matter for valuation?

Myomo is not well described by a simple revenue multiple because its future value depends on whether a specialized medical-device platform can cross from reimbursement-enabled growth to durable cash generation. The company’s reported revenue is real, gross margin is substantial, and demand indicators are measurable, but the cost structure, payer dependence, debt, and dilution risk make terminal assumptions unusually sensitive.

Which assumptions belong in a DCF model?

• Revenue growth: build from units, ASP, channel mix, backlog conversion, and recurring-source share rather than applying a single top-line rate.
• Gross margin: reflect direct billing versus wholesale mix, material savings, clinical cost, warranty expense, and overhead absorption.
• Operating leverage: test whether selling, clinical, marketing, R&D, and G&A can grow materially slower than gross profit.
• Working capital: model receivables, inventory, payer audits, and patient-delivery timing explicitly.
• Financing and dilution: include Avenue debt service, covenant constraints, warrants, pre-funded warrants, RSUs, and possible future capital raises.
• Terminal risk: use a conservative terminal framework because reimbursement policy, patent life, market development, and competitive entry remain uncertain.

The 2026 guidance range of $43 million to $46 million implies approximately 5% to 12% growth over FY2025. The more important valuation question is not whether Myomo reaches the high or low end of that range, but whether recurring referrals and manufacturing savings begin to lower cash burn structurally. A model that assumes rapid margin normalization without explaining customer acquisition, payer collections, and capital needs would miss the company’s central economic constraints.

What is the key takeaway from Myomo analysis?

Myomo has created a distinctive medical-device platform around a difficult patient population, specialized myoelectric technology, custom fabrication, and increasingly established reimbursement. The 2024 Medicare brace classification was the commercial inflection point: it expanded access, supported higher-value direct billing, and helped revenue rise from $19.2 million in FY2023 to $32.6 million in FY2024 and $40.9 million in FY2025. The company now has a clearer path to patients than it did before reimbursement, but it has not yet proven that this path produces sustainable free cash flow.

Myomo is a commercialization case study: the product must satisfy patients, clinicians, payers, regulators, manufacturers, and capital providers at once. Researchers should monitor 2026 revenue, recurring-source mix, acquisition cost, orders, backlog, gross margin, operating cash use, payer receivables, covenant compliance, and share-count growth. Together, those variables show whether the company is becoming scalable or remains dependent on external financing.